Enanta Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Enanta Pharmaceuticals

08/02/2023 02:51

* Enanta Pharmaceuticals Inc  ENTA.OQ  reported a quarterly
adjusted loss of $1.39​​ per share for the quarter ended in
December. The mean expectation of six analysts for the quarter
was for a loss of $1.59 per share.
    * Revenue fell 14.7% to $23.59 million from a year ago;
analysts
expected $22.57 million. 
    * Enanta Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $1.39​.
    * The mean earnings estimate of analysts had fallen by
about 19%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Enanta Pharmaceuticals Inc shares had risen by 13.8% this
quarter.
    * The company reported a quarterly loss of $28.99 million.
    * Wall Street's median 12-month price target for Enanta
Pharmaceuticals Inc is $64.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
8 at 02:51 a.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -1.59          -1.39          Beat
 Sep. 30 2022      -1.35          -1.27          Beat
 Jun. 30 2022      -1.39          -1.53          Missed
 Mar. 31 2022      -1.43          -1.63          Missed